Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 50.5 EUR 0.2% Market Closed
Market Cap: 10.4B EUR
Have any thoughts about
Recordati Industria Chimica e Farmaceutica SpA?
Write Note

Recordati Industria Chimica e Farmaceutica SpA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Recordati Industria Chimica e Farmaceutica SpA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Total Liabilities & Equity
€4.2B
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
11%
Newron Pharmaceuticals SpA
SIX:NWRN
Total Liabilities & Equity
€24.9m
CAGR 3-Years
-14%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
P
Pierrel SpA
MIL:PRL
Total Liabilities & Equity
€72m
CAGR 3-Years
27%
CAGR 5-Years
24%
CAGR 10-Years
1%
Friulchem SpA
MIL:FCM
Total Liabilities & Equity
€36.8m
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Shedir Pharma Srl Unipersonale
MIL:SHE
Total Liabilities & Equity
€56.1m
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
No Stocks Found

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Market Cap
10.4B EUR
Industry
Pharmaceuticals

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

REC Intrinsic Value
58.09 EUR
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Recordati Industria Chimica e Farmaceutica SpA's Total Liabilities & Equity?
Total Liabilities & Equity
4.2B EUR

Based on the financial report for Sep 30, 2024, Recordati Industria Chimica e Farmaceutica SpA's Total Liabilities & Equity amounts to 4.2B EUR.

What is Recordati Industria Chimica e Farmaceutica SpA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
11%

Over the last year, the Total Liabilities & Equity growth was -1%. The average annual Total Liabilities & Equity growth rates for Recordati Industria Chimica e Farmaceutica SpA have been 13% over the past three years , 9% over the past five years , and 11% over the past ten years .

Back to Top